

This material has been developed and funded by Novartis Pharmaceuticals UK Ltd and is intended only for UK patients with paroxysmal nocturnal haemoglobinuria (PNH) who have been prescribed iptacopan.

Support to help you start and stay on treatment

You have been prescribed FABHALTA® ▼ (iptacopan), a twice daily medication, to treat paroxysmal nocturnal haemoglobinuria (PNH). Starting a treatment and managing PNH can have challenges. That's why we have developed Connected – Stronger Together to support you at every step.

Designed with help from others living with PNH, **Connected – Stronger Together provides resources and personalised support** that addresses your unique needs as you start and continue treatment with iptacopan.

When you enrol in Connected – Stronger Together, you get access to a personalised support programme, where you choose your preferred channels for education and communication to help you:



Increase your awareness
of the symptoms and potential
complications of PNH



Learn more about your treatment with iptacopan



Understand and manage possible side effects



Set and stick with a daily treatment routine



Learn **coping strategies** for difficult emotions and expand your **support network**



Improve your communication and relationship with your healthcare team

This material does not replace the patient information leaflet (PIL) that comes with your medication. You should read the PIL carefully before you start taking this medicine because it contains important information for you.

If you have any questions, ask your doctor or care team.

Connected – Stronger Together is a patient support programme developed and funded by Novartis Pharmaceuticals UK Ltd.



Reporting side-effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the information leaflet that comes in the pack.

▼The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side-effects you may get. Please see www.mhra.gov.uk/yellowcard for instructions on how to report side effects.

Support and resources delivered the way you want them

Connected – Stronger Together provides resources and personalised support delivered through various communication channels to help you access the support you may be looking for:



Reminder text messages (SMS) to help you stay on track with treatment, and to offer motivation along the way



Emails about important topics related to PNH and treatment with iptacopan, with helpful links to additional resources



A starter brochure with important information about iptacopan dosing, side effect management, and the importance of treatment tracking and monitoring



Unlimited access to **online resources**, including important tools to help you have a good start on iptacopan and better manage your PNH



Inbound and outbound nurse calls that provide personalised informational, emotional, and logistical support

Enrol in Connected – Stronger Together today

You can sign up for any of these channels, and you can change them at any time as your needs change. Whether you are looking for information on iptacopan, practical support for sticking with your treatment routine, or strategies for managing difficult emotions, Connected – Stronger Together has the support you need.

Two simple ways to enrol:



Online Scan QR code or visit: www.fabhalta-cst.co.uk



PhoneCall **01794 331148**



Visit <u>www.fabhalta-connected-stronger-together.co.uk</u> for resources, support, and information about treatment with iptacopan, and learn about the benefits of **Connected – Stronger Together.**

U NOVARTIS

Reporting side-effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the information leaflet that comes in the pack.

▼The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side-effects you may get. Please see www.mhra.gov.uk/yellowcard for instructions on how to report side effects.